Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Mvasi gets Canadian approval

Executive Summary

Amgen has moved closer to introducing in Canada its Mvasi (bevacizumab) biosimilar rival to Genentech’s Avastin, after obtaining approval from Health Canada for 100mg/4ml and 400mg/16ml single-use vials. Stating that Mvasi’s indications were granted on the “basis of similarity” between the biosimilar and Avastin, a product monograph released by Health Canada noted that Mvasi will be used to treat metastatic colorectal cancer and locally advanced, metastatic or recurrent non-small cell lung cancer.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts